

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number  
**WO 2004/113285 A1**

(51) International Patent Classification<sup>7</sup>: **C07C 323/56,**  
A61K 31/192

[SE/SE]; AstraZeneca R & D Molndal, S-SE-431 83  
Molndal (SE).

(21) International Application Number:  
PCT/GB2004/002599

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,  
S-SE-151 85 Sodertalje (SE).

(22) International Filing Date: 16 June 2004 (16.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0314260.1 19 June 2003 (19.06.2003) GB

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE,  
BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ,  
DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX, MZ,  
NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, SY, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG,  
UZ, VC, VN, YU, ZA, ZM, ZW only): **ASTRAZENECA**  
AB [SE/SE]; Sodertalje, S-SE-151 85 (SE).

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for MG only): **ASTRAZENECA UK LIM-  
ITED** [GB/GB]; 15 Stanhope Gate, London, Greater Lon-  
don W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANDERSSON,**  
Kjell [SE/SE]; AstraZeneca R & D Molndal, S-SE-431  
83 Molndal (SE). **LINDSTEDT-ALSTERMARK,**  
Eva-Lotte [SE/SE]; AstraZeneca R & D Molndal,  
S-SE-431 83 Molndal (SE). **SORENSEN, Henrik**

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF RACEMIC 2-[[2-(4-HYDROXYPHENYL)ETHYL]THIO]-3-[4-(2-{4-  
[(METHYLSULFONYL)OXY]PHENOXY}ETHYL)PHENYL]-PROPANOIC ACID

(57) Abstract: The present invention provides a process for the preparation of substantially racemic 2-[[2-(4-hydrox-  
yphenyl)ethyl]thio]-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid which comprises reacting  
2-[[2-(4-hydroxyphenyl)ethyl]thio]-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid enriched in one  
enantiomer with a base in an inert solvent.

WO 2004/113285 A1